Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Journal for immunotherapy of cancer·2026

Same author

Brain age prediction in a multiethnic Asian population: A comparison of machine learning algorithms and their application for early-stage cognitive impairment diagnosis.

Journal of Alzheimer's disease : JAD·2026

Same author

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort.

JCO precision oncology·2026

Same author

Surgical treatment of vaginal and vulvar melanoma: a 18-year retrospective study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Same author

International real-world study of combination immunotherapy sequences in metastatic melanoma.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: May 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Vemurafenib and radiosensitization.

Lise Boussemart¹, Catherine Boivin, Joël Claveau

¹Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.

JAMA Dermatology

|May 24, 2013

Summary

Vemurafenib may cause skin reactions in previously irradiated areas, acting as a radiosensitizer and causing radiation recall dermatitis. These effects are manageable with topical corticosteroids without vemurafenib dose adjustment.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Area of Science:

Oncology
Dermatology
Pharmacology

Background:

Vemurafenib is approved for BRAFV600 metastatic melanoma.
Emerging reports detail new adverse effects with vemurafenib treatment.
Cutaneous side effects, including phototoxicity and skin reactions, are common.

Observation:

Two cases of dermatitis on previously irradiated skin in vemurafenib-treated patients are presented.
The first case showed signs of radiosensitization by vemurafenib at a low radiation dose.
The second case was diagnosed as radiation recall dermatitis occurring 30 days post-radiotherapy.

Findings:

Vemurafenib may act as a cutaneous radiosensitizer.
Vemurafenib can induce radiation recall dermatitis.
These adverse effects are typically managed with topical corticosteroids.

Implications:

Vemurafenib's potential radiosensitizing effects warrant consideration in patients with prior radiation therapy.
Topical corticosteroids are effective for managing these dermatologic adverse events.
Further research is needed to determine if other BRAF or MEK inhibitors share these pharmacodynamic interactions.